
Jason Gallagher
Editor-in-Chief at Contagion Live
ID pharmacy professor who escapes reality by bicycle. Advocate for antibiotic development. Author of Antibiotics Simplified. @jgpharmd.bsky.social
Articles
-
2 months ago |
contagionlive.com | John Parkinson |Jason Gallagher
On January 20, the Trump Administration issued an executive order announcing its withdrawal from the World Health Organization (WHO). The order stated it was, “due to the organization’s mishandling of the COVID-19 pandemic that arose out of Wuhan, China, and other global health crises, its failure to adopt urgently needed reforms, and its inability to demonstrate independence from the inappropriate political influence of WHO member states.
-
Jan 10, 2025 |
contagionlive.com | Jason Gallagher
It's trite to say elections have consequences, but those consequences rarely have substantial effects on infectious disease (ID) practice. However, 2025 may bring significant change, with apparent intent to disrupt key components of the US Department of Health and Human Services (HHS)—components critical to disease surveillance, drug development, research, and public health. The implications could be felt for generations.
-
Nov 3, 2024 |
contagionlive.com | Jason Gallagher
July 2024, we received the long-awaited results from the first of 2 studies evaluating twice-yearly injectable lenacapavir for preexposure prophylaxis (PrEP) against HIV infection. PURPOSE 1(NCT04994509), conducted in South Africa and Uganda, enrolled HIV-negative, sexually active cisgender women.
-
Mar 18, 2024 |
contagionlive.com | Jason Gallagher
Quickly—name a common infection that has a standard evidence-based treatment strategy that is usually managed by nonspecialists. To me, uncomplicated cystitis would be at the top of this list. We have had an evidence base for years about the optimal treatment of uncomplicated cystitis (at least for women).
-
Oct 23, 2023 |
contagionlive.com | Jason Gallagher
If you ask infectious diseases clinicianswhat new antibiotic they want to see, a “narrow-spectrum agent active against resistant gram-negative rods” (usually Pseudomonas) is a common reply. I admit that this is also one of my wants (along with an oral agent for multidrug-resistant [MDR] urinary tract infections). As of August, we finally have such an option.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 16K
- Tweets
- 28K
- DMs Open
- Yes